Neumora Therapeutics, Inc. share price logo

Neumora Therapeutics, Inc.

NASDAQ: NMRA

$0.47

-0.02

(-3.97%)

as on

Neumora Therapeutics, Inc. Stock Performance

as on November 11, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $0.45
    $0.49
    downward going graph

    3.56%

    Downside

    5.02%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $0.32
    $3.65
    downward going graph

    32.40%

    Downside

    682.25%

    Upside

    downward going graph

Neumora Therapeutics, Inc. share price movements today

Previous Close
$0.49
Open
$0.49
Volume
590.1K
Market Cap
$94.6M
Day's Low - High
$0.45 - $0.49
52 Week Low - High
$0.32 - $3.65

Neumora Therapeutics, Inc. Historical Returns

1 Month Return
-1.91 %
3 Month Return
-72.55 %
1 Year Return
-83.03 %
3 Year Return
-95.97 %
5 Year Return
0 %

Neumora Therapeutics, Inc. Stock Fundamentals & Key Indicators

Check Neumora Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$94.6M

EPS (TTM)

-1.23

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.38

Industry PE ratio

-3.10

PEG Ratio

-0.01

EBITDA

-207.1M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-242.28%

Neumora Therapeutics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Neumora Therapeutics, Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Neumora Therapeutics, Inc. image
Neumora Therapeutics, Inc.
StrongBuy$94.6MNA-0.380.00%0.00%
Moderna image
Moderna
Neutral$101.5B11.08%-35.4828.00%0.00%
BeOne Medicines image
BeOne Medicines
StrongBuy$46.5BNA68.2588.39%0.00%
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
StrongBuy$138.7B194.77%34.9985.57%0.00%
Regeneron image
Regeneron
Buy$93.5B46.19%19.5185.77%0.41%

Stock Returns calculator for Neumora Therapeutics, Inc. Stock including INR - Dollar returns

The Neumora Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Neumora Therapeutics, Inc. investment value today

Current value as on today

₹17,964

Returns

-₹82,036

(-82.04%)

Returns from Neumora Therapeutics, Inc. Stock

-₹83,033 (-83.03%)

Dollar Impact

₹997 (+1.00%)

Analyst Recommendation on Neumora Therapeutics, Inc. Stock

Based on 5 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 5 analysts, 100% of analysts recommend a 'BUY' rating for Neumora Therapeutics, Inc.. Average target price of $6

Neumora Therapeutics, Inc. Share Price Target

Get share price movements and forecasts by analysts on Neumora Therapeutics, Inc..

What analysts predicted

92.22%UPSIDE

Target Price

$6

Current Price

$0.4666

Analyzed by

5 Analysts

High

$7

Target

$6.00

Low

$3

Neumora Therapeutics, Inc. target price $6, a slight upside of 92.22% compared to current price of $0.4666. According to 5 analysts rating.

Indian Investors' Interest in Neumora Therapeutics, Inc. Stock

Search interest for Neumora Therapeutics, Inc. Stock has increased by 10% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:10% versus previous 30 day period

Neumora Therapeutics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
-
-
-
-
-
-
-
-
-
-
Gross Profit
-
-
-
-
-
-
-5
-
0
-
Operating Income
-60
-63
-76
-62
-70
-54
-57
-58
-52
-42
EBITDA
-53
-58
-72
-58
-67
-52
-55
-57
-51
-42
Interest Expense
-
-
-
-
-
-
0
2
1
1
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-53
-58
-72
-58
-67
-52
-56
-59
-53
-43
Income Tax Expense
-
0
0
-
0
0
-
-
0
-
Net Income
-53
-58
-72
-58
-67
-52
-56
-59
-53
-43
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Neumora Therapeutics, Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
-
-
Gross Profit
-
-
-
0
-
-5
Operating Income
-95
-237
-135
-188
-263
-241
EBITDA
-95
-236
-130
-234
-242
-233
Interest Expense
-
-
-
-
-
3
Depreciation
0
0
0
0
0
0
Income Before Tax
-99
-237
-130
-235
-243
-236
Income Tax Expense
-
-
-
0
0
0
Net Income
-99
-237
-130
-235
-243
-236
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Neumora Therapeutics, Inc. Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-53
-58
-72
-58
-67
-52
-56
-59
-53
-43
Operating Cash Flow
-42
-56
-33
-50
-59
-52
-46
-47
-46
-39
Investing Cash Flow
-150
21
156
-98
44
30
51
42
0
-
Financing Cash Flow
1
2
1
15
-
18
0
58
10
9
Change in Cash
-191
-32
125
-133
-15
-3
4
53
-35
-30

Neumora Therapeutics, Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-99
-237
-130
-235
-243
-236
Operating Cash Flow
-26
-75
-114
-163
-182
-206
Investing Cash Flow
-11
0
-168
64
-70
168
Financing Cash Flow
230
293
115
231
21
77
Change in Cash
192
217
-167
133
-231
39

Global Institutional Holdings in Neumora Therapeutics, Inc.

Check out the Institutions with significant holdings in Neumora Therapeutics, Inc..

Funds
Holdings
Kristina Burow
18.04%
Paul Berns
4.15%
BlackRock, Inc.
4.15%
Vanguard
2.92%
Joseph Edelman
2.72%
See all

Insights on Neumora Therapeutics, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 849.8% return, outperforming this stock by 932.8%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Moderna, Inc. Common Stock has given 258.1% return, outperforming this stock by 354.1%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, NMRA stock has moved down by -17.6%

About Neumora Therapeutics, Inc.

Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
OrganisationNeumora Therapeutics, Inc.
Headquarters490 Arsenal Way, Watertown, MA, 02472, US
IndustryBiotechnology
CEOJosh Pinto

Key Management of Neumora Therapeutics, Inc.

Name

Title

Mr. Michael Lee Milligan

CFO & Principal Accounting Officer

Dr. Nicholas Brandon Ph.D.

Chief Scientific Officer

Mr. Jason G. Duncan J.D.

Chief Legal & Administrative Officer

Ms. Amy Sullivan

Chief Human Resources Officer

Dr. Daljit Singh Aurora Pharm.D.

Chief Operationg & Development officer

Dr. Joshua Pinto Ph.D.

President, CEO & Director

Mr. Pablo Gersberg

Chief Information Officer

Helen Rubinstein

Head of Investor Relations

Mr. David Phillips M.B.A.

Senior Vice President & Head of Quality

Mr. Paul L. Berns

Executive Chairman

FAQs

What is Neumora Therapeutics, Inc. share price today?

Neumora Therapeutics, Inc. share price today is $0.47 as on at the close of the market. Neumora Therapeutics, Inc. share today touched a day high of $0.49 and a low of $0.45.

What is the 52 week high and 52 week low for Neumora Therapeutics, Inc. share?

Neumora Therapeutics, Inc. share touched a 52 week high of $3.65 on and a 52 week low of $0.32 on . Neumora Therapeutics, Inc. stock price today i.e. is closed at $0.47,which is 87.22% down from its 52 week high and 47.94% up from its 52 week low.

What is Neumora Therapeutics, Inc.'s market capitalisation today?

Neumora Therapeutics, Inc. market capitalisation is $0.00T as on .

How to invest in Neumora Therapeutics, Inc. Stock (NMRA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Neumora Therapeutics, Inc. on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Neumora Therapeutics, Inc. Stock (NMRA) from India?

Indian investors can start investing in Neumora Therapeutics, Inc. (NMRA) shares with as little as ₹93.917999267578 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹939.18 in Neumora Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Neumora Therapeutics, Inc. share’s latest price of $0.47 as on November 11, 2026 at 8:45 am IST, you will get 21.4316 shares of Neumora Therapeutics, Inc.. Learn more about fractional shares .